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a b s t r a c t 
Many cytokines are currently under investigation as potential target to improve cardiac function and out- 
come in the setting of acute myocardial infarction (MI) or chronic heart failure (HF). Here we aim to pro- 
vide a translational overview of cytokine inhibiting therapies tested in experimental models and clinical 
studies. In various experimental studies, inhibition of interleukin-1 (IL-1), -6 (IL-6), -8 (IL-8), monocyte 
chemoattractant protein-1 (MCP-1), CC- and CXC chemokines, and tumor necrosis factor- α (TNF- α) had 
beneﬁcial effects on cardiac function and outcome. On the other hand, neutral or even detrimental results 
have been reported for some (IL-1, IL-6, IL-8, and MCP-1). Ambivalence of cytokine function, differences in 
study designs, treatment regimens and chosen endpoints hamper the translation of experimental research 
into clinical practice. Human studies are currently limited to IL-1 β inhibition, IL-1 receptor antagonists 
(IL-1RA), IL-6 receptor antagonists (IL-6RA) or TNF inhibition. Despite favorable effects on cardiovascular 
events observed in retrospective cohort studies of rheumatoid arthritis patients treated with TNF inhibi- 
tion or IL-1RA, most prospective studies reported disappointing and inconsistent results. Smaller studies 
( n < 100) generally reported favorable results of anticytokine therapy on cardiac function, but only one of 
the larger studies ( n > 100) evaluating IL-1 β inhibition presented positive results on outcome. In conclu- 
sion, of the 10 anticytokine therapies tested in animals models beneﬁcial effects have been reported in at 
least one setting. In larger clinical studies, ﬁndings were unsatisfactory in all but one. Many anticytokine 
therapies with promising animal experimental data continue to require further evaluation in humans. 
© 2018 The Authors. Published by Elsevier Inc. 
This is an open access article under the CC BY-NC-ND license. 





























Acute myocardial infarction (MI) and chronic heart failure
HF) are associated with decreased quality of life and unfavor-
ble long-term outcome [1–3] and novel therapeutic strategies
re still needed to improve clinical outcome. After successful in-
roduction of antiplatelet inhibitors, beta-blockers, statins, and
enin-angiotensin-aldosterone inhibitors, more recently there is in-
reasing interest to target inﬂammation more speciﬁcally by im-
unomodulation or speciﬁc anticytokine treatment. 
Cardiac remodeling is one of the major contributors to progres-
ion of MI to HF and considered to be importantly mediated by
nﬂammation [4] . Epidemiological studies suggest that circulating✩ Conﬂict of interest: On behalf of all authors, the corresponding author states 
hat there is no conﬂict of interest. 
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050-1738/© 2018 The Authors. Published by Elsevier Inc. This is an open access article uoncentrations of inﬂammatory markers, such as C-reactive pro-
ein (CRP), are associated with subsequent risk of atherosclerosis
ormation, coronary heart disease (CHD) and cardiac remodeling
5] . In the setting of acute MI, elevated CRP levels are associated
ith impaired myocardial reperfusion [6] . In principle, the inﬂam-
atory response is a protective mechanism short-term but may
ead to chronic overcompensatory failure. It is a complex conjunc-
ion between innate (quick and non-speciﬁc) and adaptive (slow
nd speciﬁc) immune systems [4,7] . Upon tissue damage or en-
othelial cell stress, cardiomyocytes, leukocytes and platelets can
elease various inﬂammatory cytokines attracting antigen present-
ng cells. Antigen presenting cells such as dendritic cells, mono-
ytes and macrophages from the innate immune system will rec-
gnize released self-antigens or danger signals and start to interact
ith B and T cells from the adaptive immune system [8,9] . This
nteraction may be caused by the formation of receptor complexes
nd via cytokine production further activates and ampliﬁes the in-
tigated inﬂammatory response. Cytokines, such as interleukin-1nder the CC BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 






















































































































t  (IL-1), monocyte chemoattractant protein-1 (MCP-1), tumor necro-
sis factor- α (TNF- α) were previously found to be elevated in MI
and HF [10,11] . They are known to promote cell death of cardiomy-
ocytes and cell hypertrophy by induction of intracellular signaling
cascades such as NF- κB, JAK/STAT and PI3K pathways in leuko-
cytes. Some cytokines may even function as biomarker(s) while the
extent of elevation has been associated with outcome and degree
of cardiac injury [12,13] . Anticytokine therapy targeting inﬂamma-
tion is widely used and successful in rheumatoid arthritis [14] and
is currently an active ﬁeld of investigation for treatment of MI
and HF. Since their ﬂuctuations during the process of cardiovas-
cular remodeling and observed associations with clinical outcome,
cytokines have attracted attention as potential therapeutic targets.
The aim of this review is to provide a contemporary and transla-
tional overview of potential effects of cytokine inhibition on car-
diac function and outcome in the setting of acute MI and chronic
HF. 
Outline of this review 
For the selection of clinical studies, a total of 923 articles were
screened ( Supplements Methods ). Irrelevant articles based on arti-
cle type, study design, patient population, and drug therapy were
excluded. In total, 25 articles including 14 randomized clinical tri-
als (RCTs) were reviewed thoroughly. For selection of animal exper-
imental studies, we included search results and references of the
clinical search and initially reviewed 56 articles of which 50 arti-
cles were considered relevant and are discussed. Since there are
many pro-inﬂammatory cytokines being studied in the experimen-
tal ﬁeld, we mainly focused on those that are currently under in-
vestigation in the clinical setting. An introductory overview of cy-
tokine levels and their mechanisms in cardiovascular disease has
been given in the Supplements . 
Anticytokine therapy in experimental MI models 
IL-1 inhibition in small animals 
A variety of experimental MI models evaluated the effect of IL-
1 inhibition. Pre-treatment with IL-1 receptor antagonist (IL-1RA)
showed positive effects on left ventricular ejection fraction (LVEF)
and infarct size in a murine ischemia reperfusion model ( Fig. 1 )
[15] . IL-1 receptor 1 knockout mice (IL-1R1, one of the receptors of
the IL-1R superfamily) undergoing permanent coronary artery lig-
ation, had larger infarct size compared to controls [16] . This aligns
well with the observation that genetically engineered rat overex-
pressing IL-1RA in an ischemia reperfusion model had reduced in-
farct size and apoptosis [17] . IL-1RA overexpression in mice under-
going permanent coronary artery ligation had an equivalent effect
on cardiac function and in the infarct-remote zone collagen expres-
sion was reduced, suggesting involvement of IL-1 in cardiac ﬁbro-
sis [18] . Both pre- and post-treatment with IL-1RA have been re-
ported to exert beneﬁcial effects on cardiac function, dimensions
and infarct size after permanent coronary artery ligation and is-
chemia reperfusion in mice and rats. Anakinra (recombinant hu-
man IL-1RA inhibitor) treatment initiated in the ﬁrst weeks af-
ter permanent coronary artery ligation also resulted in improved
left ventricular (LV) dimensions and fractional shortening (FS) [19] .
These ﬁndings have been replicated in a comparable study with
immediate and delayed treatment of anakinra causing a reduction
in infarct size [20] . IL-1 inhibition with IL-1 trap, also known as
rilonacept, a long-acting IL-1 inhibiting agent, was likewise suc-
cessful in a chronic MI model. Using different dosages, less apop-
tosis and smaller infarct size was observed and LV dimensions and
FS were attenuated [21] . Moreover, speciﬁc IL-1 β inhibition after
permanent coronary artery ligation led to less LV dilatation andncreased FS [22] . Interestingly, in a larger chronic MI study, detri-
ental effects have been reported with mice having larger infarct
ize, lower collagen gene expression and more ventricular ruptures
fter treatment with a similar dose of IL-1 β antibody [23] . Taken
ogether, there appears to be evidence for both beneﬁcial as well
s detrimental effects of IL-1 inhibition on cardiac function and in-
arct size in experimental MI. 
L-6 inhibition in mice and rats 
Few studies investigated the effect of activation and inhibition
f interleukin-6 (IL-6) and its receptor. One study evaluated IL-6
eceptor antagonist (MR16-1) or placebo treatment after perma-
ent coronary artery ligation in mice [24] . FS increased, left ven-
ricular end-diastolic diameter (LVEDD) was smaller and the sur-
ival rate was higher than controls. In an opposed model using
p130 knockout mice, the IL-6 binding common receptor, increased
L-6 and STAT3 expression, LV dilatation, LV rupture and mortality
as seen compared to the wild-type [25] . The effect was attenu-
ted with an additional genetic reduction of STAT3, suggesting the
estructive mechanism behind gp130 impaired signaling is STAT3
ependent. Contradictory with previous studies, infarct size in-
reased and LVEF decreased in a different study with mice treated
ith IL-6 monoclonal antibody prior to permanent coronary artery
igation. Neutrophil inﬁltration was reduced in the treatment group
uggesting the inﬂammatory response initiated by IL-6 also has
unctional and cardioprotective properties [26] . In addition, treat-
ent with IL-6/soluble IL-6 receptor (sIL-6R) complex has reduced
ardiomyocyte apoptosis and lowered the infarct area vs. area at
isk percentage in an ischemia reperfusion model [27] . In conclu-
ion, with contradictory ﬁndings on its inhibition illustrated by im-
aired cardiac function observed after pre-treatment and opposite
ffects after post-treatment, IL-6 appears a diﬃcult target for ther-
py. 
NF- α inhibition in small and large mammals 
In various ischemia reperfusion models with TNF- α inhibitor
ost-treatment reduced MI size [28–30] . In an ex vivo study, treat-
ent with monoclonal TNF- α antibodies after a period of ischemia
n isolated rat hearts showed positive effects on LV pressure, coro-
ary ﬂow and oxygen consumption [31] . However, TNF- α blockade
ad no effect when tested in adiponectin knockout mice, whereas
diponectin supplementation did, suggesting the effect of TNF- α
nhibition is adiponectin dependent [29] . Adiponectin itself has
een shown to be cardioprotective in ischemia reperfusion and
diponectin blocks the pro-inﬂammatory effects of TNF- α, while
levated TNF- α can inhibit adiponectin production [29] . To the
ontrary, administration of low-dose TNF prior to ischemia reperfu-
ion in isolated murine hearts resulted in reduced infarct size, sug-
estive of a potential preconditioning effect [32] . One chronic MI
at model receiving TNF- α inhibition post-treatment showed bet-
er LV pressures and diastolic function compared to controls [33] .
n addition, less leukocyte inﬁltration and increased thickness of
he LV free wall in the infarct area were seen. The effects of TNF-
antagonists have also been evaluated in larger mammals, in-
luding rabbits, swine, and dogs. In one rabbit study, two groups
eceived anti-murine TNF- α sheep antibodies pre-treatment and
n one group this was combined with short periods of coronary
rtery occlusion (ischemic preconditioning) before the main coro-
ary artery procedure [34] . Infarct size was reduced in all treat-
ent groups compared to controls. The concentration of circulat-
ng TNF- α correlated with infarct size. The authors suggested that
schemic preconditioning was as effective as anti-TNF- α adminis-
ration in reducing infarct size. Anti-TNF- α treatment was again
ested before permanent coronary artery ligation in another rabbit
M.H.T. Hartman et al. / Trends in Cardiovascular Medicine 28 (2018) 369–379 371 






































t  tudy and led to less necrosis, less circulating endothelial cells and
eutralized levels of TNF- α compared to controls [35] . In a perma-
ent coronary artery balloon occlusion model in swine inducing
entricular ﬁbrillation, treatment with TNF- α inhibition resulted in
urvival rates almost twice as high [36] . In a similar study in swine,
nﬂiximab treatment after induction of ventricular ﬁbrillation and
oncomitant resuscitation was associated with higher mean arte-
ial pressure and stroke work [37] . In dog ischemia reperfusion
odels, TNF- α inhibition after coronary artery balloon occlusion,
r prior to coronary artery ligation, was associated with smaller
nfarct size [38,39] . Pre- and post-treatment with TNF- α antago-
ists in smaller and larger mammals reduced infarct size in both
schemia reperfusion and permanent myocardial ischemia models.
nly two studies reported data on cardiac function after treatment
ith TNF- α antagonists and showed improvement of LV pressures.
C and CXC chemokine inhibition in mice 
Evasin-3 is a chemokine binding protein discovered in tick
aliva. Evasin-3 binds CXCL1, CXCL8, and macrophage inﬂammatoryrotein-2 and inhibits neutrophil cell recruitment and has been
ested in experimental MI models [40] . In a model of in vivo and
x vivo coronary artery ligation lasting 30 minutes, Evasin-3 post-
reatment reduced infarct size and reactive oxygen species levels
41] . The beneﬁcial effects of post-treatment in a mouse ischemia
eperfusion model were attributed to the prevention of neutrophil
nﬁltration, which is induced by CXC chemokines. In a subsequent
tudy, Evasin-3 and Evasin-4, chemokine binding proteins inhibit-
ng CC chemokines (including CCL5 and CCL11), administration af-
er inducing permanent coronary artery ligation in mice was asso-
iated with lower levels of CXCL1 and CCL2, less leukocyte inﬁltra-
ion and smaller infarct size [42] . The effect of Evasin-4 on circulat-
ng chemokine levels was accelerated and survival after infarction
mproved compared to Evasin-3. Cardiac function did not differ be-
ween Evasin-3 and -4 groups and controls. Interestingly, direct in-
ibition of CXCL1 and receptor CXCR2 in several regimens was not
uccessful in mice [43] . Only anti-CXCR2 antibody improved LVEF
nd decreased infarct size when administered for a longer period
p to 3 weeks. Inhibition of the CXCR2 and CXCR4 binding cy-
okine, macrophage migration inhibitory factor (MIF), was further












































































































etested in a genetic ischemia reperfusion model with chimeric mice
lacking CXCR2 and wildtype mice [44] . Pre-treatment with anti-
MIF resulted in larger infarct size and impaired LVEF in wildtype
mice and in the mice generated with CXCR2 lacking bone marrow
derived inﬂammatory cells. In contrast, chimeric mice with CXCR2
lacking cardiomyocytes receiving anti-MIF treatment showed an
improved LVEF compared to chimeric mice with control antibody
treatment. Blocking MIF has detrimental effects presumably via
CXCR2 cardiomyocytes as opposed to cardioprotective effects in
CXCR2-deﬁcient cardiomyocytes. Miller et al. [45] investigated ef-
fects of genetic deletion of MIF (MIF −/ −) in an ischemia reperfusion
mouse model and observed larger infarct size compared to wild-
type mice. In conclusion, Evasin-3 and -4 post-treatment, target-
ing CC and CXC chemokines, were associated with smaller infarct
size. CXCR2 inhibition during a longer period attenuated cardiac
function in experimental MI whereas contradictory ﬁndings are re-
ported regarding inhibition of its ligand MIF. 
MCP-1 (CCL2) inhibition in mice 
Anti-MCP-1 treatment in mice, administered before and after
permanent coronary artery ligation, resulted in improved survival
and reduced LVEDD and improved FS [46] . Extracellular matrix
metalloproteinase 9 concentration, involved in collagen degrada-
tion and thereby remodeling, was lower in the anti-MCP-1 treated
group. In contrast, in transgenic MCP-1 overexpressing mice infarct
size was reduced in ischemia reperfusion experiments but not in
permanent coronary artery ligation [47] . Likewise, in an ischemia
reperfusion model with isolated hearts of MCP-1 overexpressing
transgenic mice, improved LV pressures were observed [48] . Taken
altogether, the effects of MCP-1 inhibition and overexpression in
experimental MI are ambiguous. 
CCL5 (RANTES) inhibition in mice 
Several pharmacological and genetic knock-out studies have
been undertaken to determine the effect of CCL5 inhibition. Mice
treated with anti-CCL5 after permanent coronary artery ligation or
ligation for 30 minutes resulted in improved LVEF and smaller in-
farct size [49] . A decline in infarct size was also observed in an-
other ischemia reperfusion model in which mice received CCL5
antagonist prior to reperfusion [50] . On the other hand, blocking
CCR5, a receptor binding CCL5 and others, in a knockout model had
detrimental effects [51] . Though, CCL5 was not induced, which cor-
responds with the previous study suggesting CCL5 inhibition may
exert its effects via CCR1 and not via de CCR5 receptor [50] . The
preliminary effects of CCL5 inhibition are promising but the mech-
anism or receptor of action needs to be elucidated. 
IL-8 inhibition in rabbits and rats 
Both genetic overexpression and inhibition of interleukin-8 (IL-
8) have been studied. In an ischemia reperfusion model, rabbits re-
ceived a monoclonal antibody against IL-8 prior to coronary artery
ligation that was associated with reduced infarct size [52] . In a
chronic MI model with rats, treatment with endothelial cell trans-
fusion overexpressing IL-8 receptors at several hours after perma-
nent coronary artery ligation decreased infarct size, inﬂammatory
cells and improved LVEF was observed [53] . Thus far, experimen-
tal MI studies are contradictory on the effect of IL-8 inhibition and
overexpression. nticytokine therapy in MI in humans 
L-1 inhibition 
The recombinant human IL-1RA (anakinra) is currently regis-
ered for the treatment of rheumatoid arthritis. Two pilot stud-
es and a phase 2 study with anakinra have been performed in
T-segment elevation myocardial infarction (STEMI) patients ( Table
 ). In the pilot study VCU-ART, 10 patients received anakinra
00 mg/day and showed a decrease in LV end-diastolic and end-
ystolic volume indices, compared to placebo [54] . Details on study
esign and results can be found in Table 1 . In a consecutive RCT,
0 STEMI patients undergoing percutaneous coronary intervention
PCI) were treated with anakinra 100 mg/day or placebo during
he ﬁrst 2 weeks and the primary end point, left ventricular end-
ystolic volume index, did not differ [55] . A meta-analysis com-
ining the data with the previous pilot study, VCU-ART, showed
 lower incidence of HF symptoms in the anakinra treated group
54] . In a further analysis including extended follow-up data of
hese patients, treatment was associated with decreased incidence
f new-onset HF diagnoses and death [56] . In the MRC ILA Heart
tudy, 182 acute non-ST-segment elevation myocardial infarction
NSTEMI) patients were randomized to anakinra 100 mg/day or
lacebo for a period of 2 weeks [57] . No differences were found
n levels of high sensitive C-reactive protein (hsCRP), Troponin or
on Willebrandfactor 1 week after MI. In a later publication of
he same author, it was stated that the primary endpoint, hsCRP
rea under the curve over ﬁrst 7 days, was signiﬁcantly lower [58] .
nfortunately, more major adverse cardiac events (MACE) also oc-
urred in the IL-1RA treatment group during 1-year follow-up. In
ontrast, the recent CANTOS RCT including 10,061 patients with
revious MI and hsCRP levels ≥2 mg/L showed promising results.
reatment with canakinumab, an IL-1 β targeting monoclonal anti-
ody, resulted in a lower incidence of cardiovascular events [59] .
s can be expected, fatal infection or sepsis was more prevalent in
he treatment groups. Nonetheless, fatal cancer, with almost dou-
le the incidence rate, was signiﬁcantly lower in the treatment
roups. Although future studies are needed to evaluate the safety
roﬁle and to reaﬃrm these study results, canakinumab is the
ost promising anticytokine therapy studied in MI. The double-
lind RCT VCU-ART3 in STEMI patients is currently ongoing, evalu-
ting IL-1RA treatment on CRP [60] . 
NF- α inhibition 
TNF- α antagonists (inﬂiximab, etanercept, and adalimumab) are
ommonly used anti-inﬂammatory agents and inhibit TNF- α sig-
aling by binding to its soluble receptors sTNFR1 and sTNFR2. Only
ne double-blind RCT evaluated the effect of etanercept 10 mg or
lacebo treatment in 26 acute NSTEMI patients [61] . Etanercept re-
uced neutrophil and IL-6 levels, although an increase in platelet-
onocyte aggregation was seen. Cardiac function and infarct size
ere not assessed in this study, prohibiting a hard conclusion on
he effects of etanercept. 
L-6 inhibition 
Promising results have recently been reported on the effect of
 single dose of tocilizumab, an IL-6 receptor antagonist, on the
rimary endpoint hsCRP levels in NSTEMI patients ( Table 1 ) [62] .
n this double-blind trial, Area under the curves of hsCRP and Tro-
onin T were higher in the placebo group, suggesting the inﬂam-
atory response can be attenuated by tocilizumab. Echocardiogra-
hy at 6 months follow-up showed no difference in cardiac func-
ion between the groups, although the trial was not primarily pow-
red for this endpoint. 
M.H.T. Hartman et al. / Trends in Cardiovascular Medicine 28 (2018) 369–379 373 
Table 1 
Cytokine inhibition in MI—randomized clinical trials. 
Targeted cytokine Main ﬁndings N , age Treatment Follow-up period Author, year 
Double blind RCT 
on IL-1RA after 
STEMI 
+ stable LV function, lower 
incidence of heart failure 
30 Anakinra 100 mg/day 
SC during 14 days 
compared to placebo 
treatment 
14 weeks Abbate et al., 2013 [55] 
Mean age 58.7 VCU-ART2 
Double blind RCT 
on IL-1RA in 
NSTEMI 
− no difference in levels of 
hsCRP, Troponin and 
vWF, IL-6 levels lower in 
placebo 
182 Anakinra 100 mg/day 
SC during 14 days 
compared to placebo 
treatment 
1 year Morton and Foley, 2011 
[57] Mean age 61 
Double blind RCT 
on IL-1RA after 
STEMI 
+ safe and favorably affects 
LV remodeling (higher 
LVESVI) 
10 Anakinra 100 mg/day 
SC during 14 days 
compared to placebo 
treatment 
14 weeks Abbate et al., 2010 [54] 
Mean age 47.8 VCU-ART 
Double blind RCT 
on IL-1 β after MI 
++ safe and lower 
incidence of 
cardiovascular events 
10,061 Canacinumab 50 mg, 
150 mg and 300 mg 
SC every 3 months 
Median follow-up 
3.7 years 
Ridker et al., 2017 [59] 
Mean age 61.1 CANTOS 
Double blind RCT 
on IL-6RA in 
NSTEMI 
+ / − lowers hsCRP and 
Troponin levels, no 
effects on cardiac 
function 
117 Single injection of 
tocilizumab 280 mg 
compared to placebo 
treatment 
6 months Kleveland et al., 2016 [62] 
Mean age 60 
Abbreviations : hsCRP, high-sensitive C-reactive protein; IL-1, interleukin-1; LV, left ventricular; LVESVI, left ventricular end-systolic volume index; mg, milligram; N , number; 
NSTEMI, non-ST-segment elevation myocardial infarction; RA, receptor antagonist; RCT, randomized clinical trial; SC, subcutaneous; STEMI, ST-segment elevation myocardial 













































































a  nticytokine therapy in experimental HF models 
L-1 inhibition in mice 
Only limited data are available on IL-1 inhibition in HF. One ex-
erimental model induced HF by injecting IL-1 β (3 μg/kg) causing
 signiﬁcant reduction in FS. When IL-1RA anakinra was adminis-
ered prior to this injection, LVEF and stroke volume improved in
nakinra treated mice [63] . 
NF- α inhibition in rats and dogs 
TNF- α inhibition has been evaluated in experimental HF in-
uced by Isoproterenol or chronic pacing or related to an animal
onstitution with hypertension or diabetes. In one of these exper-
mental HF models, spontaneously hypertensive and healthy rats
nderwent treatment with etanercept (TNF- α inhibitor) or placebo
uring 12 weeks [64] . Spontaneously hypertensive rats were sug-
ested to display an early stage of HF with increased relative wall
hickness and heart weight. After 12 weeks, FS did not differ, al-
hough relative wall thickness decreased and cardiac reserve in-
reased compared to controls. Furthermore, TNF- α expression was
ot affected and blood pressure was increased only in the etan-
rcept treatment group. In healthy rats, etanercept resulted in in-
reased levels of β-1-adrenergic receptor mRNA expression, sug-
esting a positive inotropic effect. These ﬁndings indicate that anti-
NF- α treatment is ineffective and may even aggravate HF. In a
ifferent HF model with diabetic rats associated with enlarged
hinned left ventricles with impaired LV function, no long-term
eneﬁcial effects within the context of cardiac function and re-
odeling were seen with etanercept [65] . Etanercept treatment
as studied yet in another HF model with isoproterenol [66] . A
ingle injection of isoproterenol, a systemic β-adrenergic receptor
gonist, is associated with myocardial damage and numerous other
haracteristics resembling HF [67] . FS and LV dilatation was indeed
meliorated in rats receiving etanercept. Noteworthy, not TNF- α
evels, but IL-1 β levels in the left ventricle were lower in the etan-
rcept group. In a distinct HF model, dogs were paced chronically
or 4 weeks and received placebo or etanercept treatment twice
 week [68] . The chronic pacing resulted in reduced LVEF and LV
ilatation. LV dilatation was less severe and LVEF was partially
reserved with etanercept treatment. Also, mitochondrial respira-ory chain enzyme complexes II and V in the etanercept group
ere completely or partially restored. DNA fragments, Terminal de-
xynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive
ells and Aldehyde levels were normalized in the etanercept group
hereby an increase was seen in the placebo group. This suggested
hat apoptosis and mitochondrial dysfunction in this HF model was
ttenuated by etanercept. Due to the variety of HF models used to
est the effect of anti-TNF- α, a general conclusion is hard to deter-
ine. 
nticytokine therapy in HF in humans 
L-1 inhibition in human 
Few RCTs, observational and cohort studies have evaluated the
ffect of TNF and IL-1 inhibition in relation to HF ( Tables 2 and
 ). In one study, 14-day treatment with IL-1 receptor antagonist
nakinra in 7 HF patients improved median peak oxygen consump-
ion [63] . A similar treatment protocol was followed in the D-HART
tudy, including 12 HF patients with preserved ejection fraction
HFpEF). Anakinra treatment led to improvement in peak oxygen
onsumption and decrease in CRP levels [69] . The subsequent RED-
ART trial including 60 HF patients treated with anakinra for 12
eeks and a different study of the same author including 30 acute
ecompensated HF patients treated for 2 weeks showed similar re-
ults with regards to peak oxygen consumption and reduction of
RP levels [70,71] . Furthermore, the investigators of the RED-HART
rial observed an improvement in LVEF with 2 week anakinra treat-
ent, but total incidence of death or readmission for HF did not
iffer among the treatment groups. In a double-blind cross-over
rial, 46 rheumatoid arthritis patients received 150 mg anakinra
aily treatment for 30 days [72] . The echocardiographic index of
V diastolic ﬁlling pressure, longitudinal strain measurements and
VEF improved after treatment with anakinra. However, these pa-
ients were not primarily diagnosed with HF; LVEF at baseline was
ithin normal range according to current guidelines [73] and for
he remaining echocardiographic parameters normal values are not
et available. One study reported a substantial improvement of car-
iac function measured a few hours after single anakinra injection
n 80 coronary artery disease patients with on average decreased
VEF at baseline [74] . In conclusion, IL-1 inhibition thus far seems
















































Cytokine inhibition in HF—(randomized) clinical trials. 
Targeted cytokine Main ﬁndings N , age Treatment Follow-up period Author, year 
RCT on IL-1RA in HF patients −/ + improved median peak oxygen 
consumption in 12 weeks 
treatment group 
60 Injection of anakinra 100 mg daily for 2 weeks or 12 weeks 
or placebo for 12 weeks 
24 weeks Van Tassell et al., 
2017 [70] Median age 57 and 
55 (IL-1RA groups) RED-HART 
Double blind RCT on IL-1RA in 
ADHF patients 
+ reduction in CRP 30 Median age 60 
(IL1RA group) 
Injection of anakinra 100 mg twice daily during 3 days and 
once daily during following 11 days compared to placebo 
14 days Van Tassell et al., 
2016 [71] 
Clinical trial on IL-1RA in HF 
patients 
−/ + improved median peak oxygen 
consumption 
7 Anakinra 100 mg/day SC during 14 days 2 weeks Van Tassell et al., 
2012 [63] Mean age 48 
Double blind crossover RCT on 
IL-1RA in HFpEF patients 
+ improved peak oxygen 
consumption, reduction in CRP 
12 Anakinra 100 mg/day SC during 14 days or placebo 
treatment followed by alternative treatment 
2 weeks Van Tassell et al., 
2014 [69] Median age 62 
Double blind (R)CT on IL-1RA in RA 
patients 
+ increase in LV performance 
(E/Em, LongS and LongSRS) 
46 Single injection (randomized) and 30 days 
(non-randomized) anakinra 150 mg SC treatment 
compared to prednisolone treatment 
1 month Ikonomidis et al., 
2011 [72] Mean age 56 
Double blind crossover IL-1RA RCT 
in CAD patients with RA 
+ increase in LVEF, improved LV 
myocardial deformation and 
twisting 
60 Single injection of anakinra 100 mg SC or placebo followed 
by the alternative treatment after 48 hours 
3 hours Ikonomidis et al., 
2014 [74] Mean age 59.5 
Double blind RCT on TNFi 
treatment in HF patients 
− no beneﬁt of etanercept on 
death/HF hospitalization 
2048 Etanercept 25 mg SC once, twice or three times weekly, 
compared to placebo treatment 
24 weeks Mann et al., 2004 
[89] Mean age 63.5 
RENEWAL 
Double blind RCT on TNFi 
treatment in HF patients 
− no improvement, possible CHF 
worsening, LVEF improved with 
5 mg/kg 
150 Inﬂiximab 5 mg/kg or 10 mg/kg IV at baseline, week 2 and 
week 6 compared to placebo treatment 
28 weeks Chung et al., 2003 
[88] Mean age 61.4 
ATTACH 
Double blind RCT on TNFi 
treatment in HF patients 
+ signiﬁcant dose-dependent 
improvement in LV structure and 
function 
47 Etanercept 5 mg/m 2 , 12 mg/m 2 SC twice weekly for 3 
months compared to placebo treatment 
3 months Bozkurt et al., 2001 
[85] Mean age 55.0 
Controlled clinical trial on TNFi in 
CHF patients 
+ improved systemic endothelial 
vasodilator capacity 
18 Single dose of etanercept 25 mg SC compared to controls 
without treatment 
1 week Fichtlscher-er et al., 
2001 [87] Mean age 53.6 
Double blind RCT on TNFi 
treatment in HF patients 
+ signiﬁcant improvement of LVEF 
in 4 or 10 mg/m 2 group 
18 Single infusion of etanercept 1, 4 or 10 mg/m 2 IV or 
placebo treatment 
2 weeks Deswal et al., 1999 
[86] Mean age 63.3 
Abbreviations : ADHF, acute decompensated heart failure; CAD, coronary artery disease; CHF, congestive heart failure; CRP, C-reactive protein; E, early transmitral ﬂow velocity; Em, early diastolic mitral annulus velocity; HF, heart 
failure; IV, intravenously; kg, kilogram; LongS, longitudinal end-systolic strain; LongSRS, longitudinal peak systolic strain rate; LV, left ventricular; LVEF, left ventricular ejection fraction; mg, milligram; m 2 , square meters; N , 
number; RA, rheumatoid arthritis; RCT, randomized clinical trial; SC, subcutaneous; TNFi, TNF inhibitors. 
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Table 3 
Cytokine inhibition and CVD—cohort and retrospective studies. 
Targeted cytokine Main ﬁndings N , age Treatment Follow-up 
period 
Author, year 
Cohort study on TNFi 
in RA patients 
++ modest increase in LVEF 
and reduced biochemical HF 
markers 
23 Inﬂiximab 3 mg/kg body 
weight per infusion every 
8 weeks 
1 year Kotyla et al., 2012 
[76] Mean age 51.3 
Cohort study on TNFi 
in RA patients and 
CV events 
++ reduced risk of non-fatal 
and fatal cardiovascular 
events 
10,156 TNFi treatment in person 




Kremer, 2011 [82] Mean age 59 
Cohort study on TNFi 
in RA patients and 
HF incidence 
+ no increased risk of 
(worsening) HF 




treatment ( n = 1491) 
3 years Listing et al., 2008 
[79] Mean age 53.7 
Cohort study on TNFi 
in elderly RA patients 
and HF incidence 
− increased risk HF 
hospitalization and 
exacerbation, TNFi treated 
patients had more severe RA 
1002 At least one prescription of 
etanercept, inﬂiximab 
and adalimumab 
compared to MTX using 
controls ( n = 5593) 
Mean 1.6/1.7 
years in HF 
Setoguchi et al., 
2008 [80] Mean age 73/77 
in HF 
Cohort study on TNFi 
and MI incidence in 
RA patients 
−/ + no difference in MI 
incidence, but reduced 
incidence of MI in responders 
10,829 TNFi treatment of minimal 
6 months ( n = 8659) 
compared to DMARD 
treatment ( n = 2170) 
Mean 18 
months 
Dixon et al., 2007 
[106] Mean age 56.8 
Retrospective study 
TNFi and 
exacerbation of CHF 
− no difference between CHF, 
but mortality rates 
non-signiﬁcantly different 
103 At least one dose of 
inﬂiximab, adalimumab 
or etanercept compared 
to RA and non-RA 
controls ( n = 200) 
max. 4 years Cole et al., 2007 
[77] Mean age 58.7 
Retrospective study on 
TNFi and prevalence 
of HF in RA/CD 
patients 
−/ + no signiﬁcant increase in 
HF incidence 
4018 At least three prescriptions 
for etanercept or 
inﬂiximab compared to 
controls 
15/21 months Curtis et al., 
2007 [78] . Mean age 
RA 40/ 38 
Retrospective study on 
TNFi in RA patients 
and CVD risk 
+ risk of CVD lower in TNF 
blocker treated RA patients 
983 TNFi treatment ( n = 531) 
compared to no TNFi 
treatment patients 
( n = 543) 
max. 2 years Jacobsson et al., 
2005 [84] Mean age 58 
Cohort study on TNFi 
in RA patients and 
HF incidence 
+ HF less common in TNFi 
treated RA patients 
13,171 Inﬂiximab or etanercept 
treatment compared to 
no TNFi treated controls 
2 years Wolfe and 
Michaud, 2004 
[83] 
Mean age 61 
Abbreviations : CD, Crohn’s disease; CHF, congestive heart failure; CV, cardiovascular; CVD, cardiovascular disease; DMARD, disease-modifying antirheumatic drugs; HF, heart 
failure; kg, kilogram; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MTX, Methotrexate; mg, milligram; N, number; RA, rheumatoid arthritis; RCT, ran- 



















































Tently evaluating improvement of peak oxygen consumption at 3
onths after canakinumab in a selected group of patients with
rior MI, elevated hsCRP, reduced LVEF and symptomatic HF [75] . 
NF- α inhibition in human 
Few small and larger cohort studies have focused on the po-
ential beneﬁcial effect of TNF inhibition on cardiac function and
ardiovascular endpoints. In one of these cohort studies, 23 fe-
ale rheumatoid arthritis patients without overt or latent history
f HF underwent inﬂiximab treatment for 1 year and LVEF in-
reased signiﬁcantly [76] . As mean LVEF was still within the nor-
al range, it may be premature to extrapolate these results to
linical overt HF. In an observational study of 303 rheumatoid pa-
ients and controls, no difference was found in mortality and the
ncidence or worsening of HF [77] . Results from a larger obser-
ational study in 4018 rheumatoid arthritis and Crohn’s disease
atients were also neutral. The risk for HF was non-signiﬁcantly
ncreased in patients receiving TNF inhibition compared to non-
iologicals [78] . In a similar neutral study, 2757 rheumatoid arthri-
is patients receiving either inﬂiximab, etanercept or adalimumab
ere compared to 1491 patients receiving non-biological disease-
odifying drugs (DMARDs) regarding the incidence or worsening
f HF [79] . When corrected for cardiovascular disease (CVD) risk
actors, increased incidence of HF was mainly related to disease
ctivity scores. There was no signiﬁcant risk related to TNF inhi-
ition. The authors suggested that anti-TNF- α treatment is moreeneﬁcial than harmful in the context of risk of HF. One study
eported negative effects of TNF inhibition on HF hospitalizations
n 1002 rheumatoid arthritis elderly patients compared to 5593
ethotrexate users [80] . Baseline characteristics of TNF inhibition
s. methotrexate users showed that patients taking TNF inhibitory
rugs had more severe rheumatoid arthritis, indicated by higher
RP levels, more co-medication or injections and more comorbidi-
ies, though statistical signiﬁcance was not reported. In addition,
he study was not randomized and selection bias in TNF inhibitory
rug prescription reserved to patients with more severe disease
ould have inﬂuenced the results. Methotrexate may also be a sub-
ptimal control treatment as it is reported to reduce incidence of
ardiovascular events [81] . In a cohort study of Dixon et al., the
ncidence of MI was reduced in responders to TNF inhibitory treat-
ent. In addition, in one of the larger cohort studies in 10,156
heumatoid arthritis patients, the risk of non-fatal (MI) and fatal
ardiovascular events was lower in the TNF inhibition group com-
ared to patients taking DMARDs [82] . Positive effects were also
bserved in a study including 13,171 rheumatoid arthritis and 2568
steoarthritis patients and in a smaller cohort showing a lower HF
revalence in TNF inhibitory drug treated patients [83,84] . When
re-existing CVD was absent, there was a low risk of HF unrelated
o TNF inhibitory therapy. However, age, sex and comorbidity dif-
ered signiﬁcantly between the TNF inhibitory drug and non-TNF
nhibitory drug-treated groups so it remains to be determined if
NF inhibition lowers the risk for HF in these patients. 




























































































































r  A RCT including 47 HF patients for safety and tolerability of
etanercept showed LVEF improvement in a dose-dependent man-
ner [85] . In a similar double-blind RCT including 18 HF patients, a
single intravenous injection of etanercept was associated with im-
provement of LVEF [86] and in a different set of 18 congestive HF
patients, etanercept improved endothelial vasodilator capacity [87] .
In another RCT, 150 patients with HF NYHA class III-IV and LVEF ≤
35% received placebo or inﬂiximab treatment 5 mg/kg or 10 mg/kg
at baseline, week 2 and week 6 [88] . LVEF increased in the 5 mg/kg
inﬂiximab group, but the primary endpoint, clinical functional sta-
tus after 2 weeks, did not improve. Conversely, 10 mg/kg inﬂiximab
treatment was associated with increased risk for HF hospitalization
or death of any cause at 28 weeks. 
To evaluate the effect of etanercept on HF hospitalization and
death, data were combined of two RCTs; RECOVER and RENAIS-
SANCE, including 1366 HF patients receiving placebo or etanercept
25 mg once, twice or three times a week [89] . Both studies were
prematurely stopped because of a lack of beneﬁt. Etanercept treat-
ment did not reduce mortality or HF hospitalizations. The results
did not change after subgroup analyses for NYHA class or LVEF. 
In smaller RCTs, TNF- α antagonists ameliorated cardiac func-
tion. However, this positive effect is absent in previously men-
tioned large RCTs. In high dose, TNF- α antagonists seem to have
adverse effects on clinical outcome. To summarize, TNF- α inhibi-
tion in HF patients did improve cardiac function in several smaller
studies and is more likely to have a beneﬁcial effect on cardiovas-
cular events in patients with rheumatoid arthritis, but has failed
to have such an effect in large RCTs. There are currently no large
studies ongoing that evaluate TNF- α inhibition treatment in HF. 
Discussion 
In a wide range of experimental animal models of MI and in
various HF models, cytokine inhibition has shown promising re-
sults. Few clinical studies investigated the effects of anticytokine
therapy in MI and HF patients. Larger clinical trials to date have
failed to show an improvement on cardiac function and outcome,
except the CANTOS trial, with less cardiovascular events in MI pa-
tients treated with canakinumab. Several explanations are possible
to explain this failure of translation from animal studies to human
trials. First of all, the association of cytokines with MI and HF is
not completely elucidated. The time course of cytokine activation
and elevation may appear obvious at ﬁrst glance; however it is not
clear whether, for instance, the duration of ischemia and the de-
gree of successful reperfusion (or co-medication) has an impact on
the inter- and intra-individual biochemical curves of cytokine lev-
els. The complex pathways underlying cytokine activation and in-
teractions are still only partly understood. The presence of poten-
tial negative feedback loops correcting hormone imbalances, such
as SOCS3 inhibiting IL-6 [90] , are not yet clariﬁed for most cy-
tokines involved in MI and HF and its presence and function are
not readily translatable from animals to humans [91] . Furthermore,
inhibition of some cytokines may lead to increased expression of
other cytokines [64] . When looking at effects of anticytokine ther-
apy, levels of related cytokines should therefore also be taken into
account. 
Another complexity is that many cytokines appear to have an
ambivalent role. The function and effects of cytokine activation
could be time-dependent, as is contemplated for instance for IL-6
[92] . Prolonged activation and excessive cytokine production may
be detrimental. Pro-inﬂammatory effects are counterbalanced by
anti-inﬂammatory downstream signaling, as in the case of TNF-
α [93,94] , and selective inhibition of pro-inﬂammatory pathways
is therefore challenging. In addition, other agents not discussed
in this review, such as rapamycin, an immunosuppressive agent
inhibiting mammalian target of rapamycin (mTOR), could have aey position in the inﬂammatory chain reaction. Rapamycin is sup-
osed to have anti-atherosclerotic effects and inhibits different cy-
okines, including MCP-1 [95,96] . Further studies are needed to
valuate the potential therapeutic value of rapamycin and other
gents involved in the inﬂammatory cascade in patients with MI
nd HF. 
At times, effects of anticytokine therapy and cytokine over-
xpression were in disagreement. Both anti-MCP-1 treatment
46] and MCP-1 overexpression [47] showed positive effects on
ardiac function. Ischemia reperfusion and permanent coronary
rtery ligation models might have different effects on cytokine
ignaling. Lower cytokine levels have been reported in mice un-
ergoing ischemia reperfusion vs. permanent coronary artery lig-
tion [97] . Hypothetically, when reperfusion is achieved, the cy-
okine burst is interrupted together with the initial inﬂammatory
esponse that is associated with beneﬁcial effects on myocardial
ealing [98] . Therefore, cytokine overexpression might have a place
n ischemia reperfusion, whereas anticytokine treatment is more
ensible in chronic MI models. Pre-treatment could also downreg-
late cytokine receptors and after a second stimulation caused by
nfarction cardiomyocytes may be less prone to cytokine activa-
ion. Yet, in the later phase after MI, the CANTOS trial showed that
 selected group of MI patients with increased inﬂammatory re-
ponse did beneﬁt from the IL-1 β antibody canakinumab. In a pre-
ious study in diabetes patients, canakinumab reduced inﬂamma-
ory markers IL-6 and hsCRP, without an effect on LDL-cholesterol
59] . These studies together endorse the hypothesis that inhibition
f inﬂammation prevents atherothrombosis, without a major in-
uence on other factors involved in this process, such as choles-
erol. In contrast to other studies, the CANTOS trial only included
atients with elevated levels of the inﬂammatory marker hsCRP.
t makes sense that in order to be effective the target inﬂamma-
ory cytokine(s) of a particular drug should be elevated in the ﬁrst
lace. To which extent the > 20% current smokers in the CANTOS
rial might explain the persistent pro-inﬂammatory response and
f canakinumab has additional positive effects on top of quitting
moking in these patients remains unknown. 
In some of the studies described, inhibition of cytokines or
ts receptors had contradictory consequences and interacting path-
ays involved in inhibition of each cytokine are as yet not cleared
p. This prohibits making a general conclusion on the responsible
argets and potential clinical use of anticytokine therapy. Different
reatment regimens are practiced. In experimental MI mode, tim-
ng and duration of treatment vary widely. This is illustrated by a
odel where mice received anti-MCP-1 gene therapy 3 days before
nd 14 days after coronary artery ligation [46] . Effective plasma
oncentrations of the MCP-1 receptor binding protein are reached
or 14 days after the injection, explaining the choice for this treat-
ent regimen. Instead of long-lasting treatment, others focused on
re-treatment [15] , or short-term post-treatment [28] . After initial
nﬂammatory response in MI, a second cytokine burst has been ob-
erved after 8 days [98] . Hence, the optimal timepoint to interfere
ith pro-inﬂammatory effects of cytokines might also be after the
rst week, which is barely studied in the discussed experimental
I models. 
Other explanations for observed discrepancies in MI models
ay be the different design, namely ischemia reperfusion vs. per-
anent coronary artery ligation. Ischemia reperfusion is believed
o trigger a more pronounced inﬂammatory response [99] . For in-
tance, contradictive ﬁndings have been reported for IL-6 and IL-8
nhibition. In addition, anti-inﬂammatory properties have been as-
ribed to IL-8 [100] . Hypothetically, anti-inﬂammatory actions by
L-6R inhibition and IL-8 overexpression may have positive effects
n cardiac function during chronic MI while the opposite is true
uring ischemia reperfusion. Again, in experimental HF, a wide va-
iety of models was used. In one study, HF was induced by inject-


























































































































 ng IL-1 β and at the same time IL-1RA was administered [63] . As
F is a complicated disease with many underlying factors, it may
e too simplistic to imitate and evaluate treatment in a model with
ddition and inhibition of a single cytokine. The dog model with
hronic overpacing [68] might be a good model for HF caused by
trium ﬁbrillation, but may not account for other etiologies linked
o HF. Recently, guidelines have been proposed to enhance similar-
ty of experimental animal studies and human HF and might help
n providing a structured approach for translation to humans [101] .
Chosen endpoints in experimental MI and HF were also dis-
arate. In experimental models, applied methods and timing of the
valuation of the inﬂammatory response and cardiac remodeling
ere very different. To illustrate, in an ischemia reperfusion model,
he inﬂammatory response was studied and TNF- α, IL-1 β , and IL-6
ere markedly upregulated 6 hours after MI [102] . The authors of
his study endorsed the assessment of inﬂammatory mediators to
e performed during the ﬁrst 3 days. They also recommended that
ssessment of dilatative remodeling should take place at least 4
eeks after MI. LV dilatation increased signiﬁcantly between 1 and
 weeks after MI reﬂecting progressive LV remodeling. In many of
he previous experimental models, these criteria for measuring LV
ilatation at a later time point are not met. 
Again, chosen endpoints in clinical MI and HF studies differ
rom each other and from experimental endpoints. This makes it
ven harder to judge if experimental ﬁndings can be readily trans-
ated to humans. Also, publication bias in experimental studies
ould play a part in the neutral results found in humans. In the
uropean Society of Cardiology guidelines, LVEF is stated as an im-
ortant prognostic parameter after MI [103] . However, surrogate
ndpoints, including LVEF, might not be good representatives for
ong-term outcome. In the reviewed experimental animal studies
egarding anticytokine therapy in MI, endpoints vary widely. Apart
rom enzymatic and functional infarct size and LVEF, other param-
ters, such as LV dilatation, LV pressures, LV mass and stroke work,
re used to evaluate treatment effects. In the two smaller clinical
I studies, positive effects of IL-1RA were seen on NYHA class, LV
imensions, incidence of HF and death. In one larger study, they
ound no effects on Troponin levels 1 week after NSTEMI and the
ncidence of MACE after 1-year follow-up did not differ. In HF, re-
uced LVEF is generally associated with worse outcome [104] . In
FpEF, important predictors of HF hospitalization and cardiovascu-
ar death were LV hypertrophy, increased pulmonary artery and LV
lling pressures [105] . The reviewed experimental HF model evalu-
ted effects of IL-1RA and TNF inhibition on LVEF, FS, LV dilatation
nd stroke work. Human studies on anti-TNF- α inhibition mainly
ocused on LVEF, NYHA class, HF hospitalizations and death. 
onclusion and future perspectives 
In this review we summarize the rapidly developing ﬁeld of
nticytokine therapy in cardiovascular disease and highlighted the
ontradictory ﬁndings in experimental MI and HF compared to the
eutral results in clinical studies. In various experimental studies,
nhibition of IL-1, -6, -8, MCP-1, CC chemokines, CXC chemokines
nd TNF- α had profound beneﬁcial effects on cardiac function and
utcome. On the other hand, neutral or even detrimental results
ave been reported for some (IL-1, IL-6, IL-8, and MCP-1) of these
ytokines. Ambivalence of cytokine function, differences in study
esigns, species, treatment regimens, and chosen endpoints appear
o hamper the successful translation of experimental research into
linical practice. In the clinical setting, only TNF- α inhibition, IL-
RA, IL-1 β inhibition and IL-6RA have been tested so far. Promis-
ng results were seen in smaller studies, but until now only one
arge RCT showed positive results on outcome. Many other anti-
ytokine therapies with encouraging animal experimental data re-
uire further evaluation in humans, but the ﬁrst clinical studiesuggest this translation can be troublesome. We recommend in-
estigators of future clinical MI and HF studies to carefully con-
ider the intensity of treatment as well as the treatment period
nd monitor a set of related cytokine levels throughout and after
he treatment period. Furthermore, inclusion of patients should be
ased on a pre-speciﬁed number of primary end-point events, such
s reinfarction, incidence of HF, readmission for HF, and cardiovas-
ular death. Widely accepted surrogate endpoints that have been
hown to be strongly related to outcome and are also frequently
sed in experimental studies, e.g., LVEF and infarct size, may be
ore suited in smaller clinical trials. 
ppendix A. Supporting information 
Supplementary data associated with this article can be found in
he online version at doi:10.1016/j.tcm.2018.02.003 . 
eferences 
[1] Bucholz EM , Butala NM , Rathore SS , Dreyer RP , Lansky AJ , Krumholz HM . Sex
differences in long-term mortality after myocardial infarction: a systematic
review. Circulation 2014;130:757–67 . 
[2] Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) The sur-
vival of patients with heart failure with preserved or reduced left ventric-
ular ejection fraction: an individual patient data meta-analysis. Eur Heart J
2012;33:1750–7 . 
[3] Braunwald E . Heart failure. JACC Heart Fail 2013;1:1–20 . 
[4] Gjesdal O , Bluemke DA , Lima JA . Cardiac remodeling at the population lev-
el—risk factors, screening, and outcomes. Nat Rev Cardiol 2011;8:673–85 . 
[5] Kaptoge S , Di Angelantonio E , Lowe G , Pepys MB , Thompson SG , et al. , Emerg-
ing Risk Factors Collaboration C-reactive protein concentration and risk of
coronary heart disease, stroke, and mortality: an individual participant meta–
analysis. Lancet 2010;375:132–40 . 
[6] Hoffmann R , Suliman H , Haager P , Christott P , Lepper W , Radke PW , et al. As-
sociation of C-reactive protein and myocardial perfusion in patients with
ST-elevation acute myocardial infarction. Atherosclerosis 2006;186:177–83 . 
[7] Kleinbongard P , Heusch G , Schulz R . TNFalpha in atherosclerosis, myocardial
ischemia/reperfusion and heart failure. Pharmacol Ther 2010;127:295–314 . 
[8] Courties G , Moskowitz MA , Nahrendorf M . The innate immune system after
ischemic injury: lessons to be learned from the heart and brain. JAMA Neurol
2014;71:233–6 . 
[9] Valeur HS , Valen G . Innate immunity and myocardial adaptation to ischemia.
Basic Res Cardiol 2009;104:22–32 . 
[10] Correia LC , Andrade BB , Borges VM , Clarencio J , Bittencourt AP , Freitas R ,
et al. Prognostic value of cytokines and chemokines in addition to the
GRACE Score in non-ST-elevation acute coronary syndromes. Clin Chim Acta
2010;411:540–5 . 
[11] Buyukkaya E , Poyraz F , Karakas MF , Kurt M , Akcay AB , Akpinar I , et al. Useful-
ness of monocyte chemoattractant protein-1 to predict no-reﬂow and three-
-year mortality in patients with ST-segment elevation myocardial infarc-
tion undergoing primary percutaneous coronary intervention. Am J Cardiol
2013;112:187–93 . 
[12] Kehmeier ES , Lepper W , Kropp M , Heiss C , Hendgen-Cotta U , Balzer J ,
et al. TNF-alpha, myocardial perfusion and function in patients with ST-seg-
ment elevation myocardial infarction and primary percutaneous coronary in-
tervention. Clin Res Cardiol 2012;101:815–27 . 
[13] Theroux P , Armstrong PW , Mahaffey KW , Hochman JS , Malloy KJ , Rollins S ,
et al. Prognostic signiﬁcance of blood markers of inﬂammation in patients
with ST-segment elevation myocardial infarction undergoing primary angio-
plasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA
trial. Eur Heart J 2005;26:1964–70 . 
[14] Choy E , Ganeshalingam K , Semb AG , Szekanecz Z , Nurmohamed M . Cardio-
vascular risk in rheumatoid arthritis: recent advances in the understanding
of the pivotal role of inﬂammation, risk predictors and the impact of treat-
ment. Rheumatology (Oxford) 2014;53:2143–54 . 
[15] Toldo S , Schatz AM , Mezzaroma E , Chawla R , Stallard TW , Stallard WC ,
et al. Recombinant human interleukin-1 receptor antagonist provides cardio-
protection during myocardial ischemia reperfusion in the mouse. Cardiovasc
Drugs Ther 2012;26:273–6 . 
[16] Abbate A , Salloum FN , Van Tassell BW , Vecile E , Toldo S , Seropian I , et al. Al-
terations in the interleukin-1/interleukin-1 receptor antagonist balance mod-
ulate cardiac remodeling following myocardial infarction in the mouse. PLoS
One 2011;6:e27923 . 
[17] Suzuki K , Murtuza B , Smolenski RT , Sammut IA , Suzuki N , Kaneda Y ,
et al. Overexpression of interleukin-1 receptor antagonist provides cardio-
protection against ischemia-reperfusion injury associated with reduction in
apoptosis. Circulation 2001;104 I308-I3 . 
[18] Murtuza B , Suzuki K , Bou-Gharios G , Beauchamp JR , Smolenski RT , Par-
tridge TA , et al. Transplantation of skeletal myoblasts secreting an IL-1 in-
hibitor modulates adverse remodeling in infarcted murine myocardium. Proc
Natl Acad Sci U S A 2004;101:4216–21 . 


























































































































 [19] Salloum FN , Chau V , Varma A , Hoke NN , Toldo S , Biondi-Zoccai GG ,
et al. Anakinra in experimental acute myocardial infarction—does dosage or
duration of treatment matter? Cardiovasc Drugs Ther 2009;23:129–35 . 
[20] Abbate A , Salloum FN , Vecile E , Das A , Hoke NN , Straino S , et al. Anakinra,
a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in
experimental acute myocardial infarction. Circulation 2008;117:2670–83 . 
[21] Van Tassell BW , Varma A , Salloum FN , Das A , Seropian IM , Toldo S , et al. In-
terleukin-1 trap attenuates cardiac remodeling after experimental acute my-
ocardial infarction in mice. J Cardiovasc Pharmacol 2010;55:117–22 . 
[22] Abbate A , Van Tassell BW , Seropian IM , Toldo S , Robati R , Varma A , et al. In-
terleukin-1beta modulation using a genetically engineered antibody prevents
adverse cardiac remodelling following acute myocardial infarction in the
mouse. Eur J Heart Fail 2010;12:319–22 . 
[23] Hwang MW , Matsumori A , Furukawa Y , Ono K , Okada M , Iwasaki A ,
et al. Neutralization of interleukin-1beta in the acute phase of myocardial in-
farction promotes the progression of left ventricular remodeling. J Am Coll
Cardiol 2001;38:1546–53 . 
[24] Kobara M , Noda K , Kitamura M , Okamoto A , Shiraishi T , Toba H , et al. An-
tibody against interleukin-6 receptor attenuates left ventricular remodelling
after myocardial infarction in mice. Cardiovasc Res 2010;87:424–30 . 
[25] Hilﬁker-Kleiner D , Shukla P , Klein G , Schaefer A , Stapel B , Hoch M ,
et al. Continuous glycoprotein-130-mediated signal transducer and activa-
tor of transcription-3 activation promotes inﬂammation, left ventricular rup-
ture, and adverse outcome in subacute myocardial infarction. Circulation
2010;122:145–55 . 
[26] Muller J , Gorressen S , Grandoch M , Feldmann K , Kretschmer I , Lehr S ,
et al. Interleukin-6-dependent phenotypic modulation of cardiac ﬁbroblasts
after acute myocardial infarction. Basic Res Cardiol 2014;109 440-014-0440-y.
Epub 2014 Sep 19 . 
[27] Matsushita K , Iwanaga S , Oda T , Kimura K , Shimada M , Sano M , et al. Inter-
leukin-6/soluble interleukin-6 receptor complex reduces infarct size via in-
hibiting myocardial apoptosis. Lab Invest 2005;85:1210–23 . 
[28] Sugano M , Hata T , Tsuchida K , Suematsu N , Oyama J , Satoh S , et al. Local
delivery of soluble TNF-alpha receptor 1 gene reduces infarct size following
ischemia/reperfusion injury in rats. Mol Cell Biochem 2004;266:127–32 . 
[29] Liu S , Yin T , Wei X , Yi W , Qu Y , Liu Y , et al. Downregulation of adiponectin
induced by tumor necrosis factor alpha is involved in the aggravation
of posttraumatic myocardial ischemia/reperfusion injury. Crit Care Med
2011;39:1935–43 . 
[30] Toufektsian MC , Robbez-Masson V , Sanou D , Jouan MG , Ormezzano O , de
Leiris J , et al. A single intravenous sTNFR-Fc administration at the time of
reperfusion limits infarct size—implications in reperfusion strategies in man.
Cardiovasc Drugs Ther 2008;22:437–42 . 
[31] Gurevitch J , Frolkis I . Tumor necrosis factor-alpha is released from the
isolated heart undergoing ischemia and reperfusion. J Am Coll Cardiol
1996;28:247–52 . 
[32] Tanno M , Gorog DA , Bellahcene M , Cao X , Quinlan RA , Marber MS . Tumor
necrosis factor-induced protection of the murine heart is independent of
p38-MAPK activation. J Mol Cell Cardiol 2003;35:1523–7 . 
[33] Berry MF , Woo YJ , Pirolli TJ , Bish LT , Moise MA , Burdick JW , et al. Adminis-
tration of a tumor necrosis factor inhibitor at the time of myocardial infarc-
tion attenuates subsequent ventricular remodeling. J Heart Lung Transplant
2004;23:1061–8 . 
[34] Belosjorow S , Bolle I , Duschin A , Heusch G , Schulz R . TNF-alpha antibodies
are as effective as ischemic preconditioning in reducing infarct size in rabbits.
Am J Physiol Heart Circ Physiol 2003;284:H927–30 . 
[35] Li D , Zhao L , Liu M , Du X , Ding W , Zhang J , et al. Kinetics of tumor necrosis
factor alpha in plasma and the cardioprotective effect of a monoclonal anti-
body to tumor necrosis factor alpha in acute myocardial infarction. Am Heart
J 1999;137:1145–52 . 
[36] Niemann JT , Youngquist ST , Shah AP , Thomas JL , Rosborough JP . TNF-alpha
blockade improves early post-resuscitation survival and hemodynamics in a
swine model of ischemic ventricular ﬁbrillation. Resuscitation 2013;84:103–7 .
[37] Niemann JT , Youngquist S , Rosborough JP , Shah AP , Phan QT , Filler SG . Inﬂix-
imab attenuates early myocardial dysfunction after resuscitation in a swine
cardiac arrest model. Crit Care Med 2010;38:1162–7 . 
[38] Gu Q , Yang XP , Bonde P , DiPaula A , Fox-Talbot K , Becker LC . Inhibition of TN-
F-alpha reduces myocardial injury and proinﬂammatory pathways following
ischemia-reperfusion in the dog. J Cardiovasc Pharmacol 2006;48:320–8 . 
[39] Yu X , Patterson E , Huang S , Garrett MW , Kem DC . Tumor necrosis factor al-
pha, rapid ventricular tachyarrhythmias, and infarct size in canine models of
myocardial infarction. J Cardiovasc Pharmacol 2005;45:153–9 . 
[40] Deruaz M , Frauenschuh A , Alessandri AL , Dias JM , Coelho FM , Russo RC ,
et al. Ticks produce highly selective chemokine binding proteins with anti-
inﬂammatory activity. J Exp Med 2008;205:2019–31 . 
[41] Montecucco F , Lenglet S , Braunersreuther V , Pelli G , Pellieux C , Montessuit C ,
et al. Single administration of the CXC chemokine-binding protein Evasin-3
during ischemia prevents myocardial reperfusion injury in mice. Arterioscler
Thromb Vasc Biol 2010;30:1371–7 . 
[42] Braunersreuther V , Montecucco F , Pelli G , Galan K , Proudfoot AE , Belin A ,
et al. Treatment with the CC chemokine-binding protein Evasin-4 improves
post-infarction myocardial injury and survival in mice. Thromb Haemost
2013;110:807–25 . 
[43] Oral H , Kanzler I , Tuchscheerer N , Curaj A , Simsekyilmaz S , Sonmez TT ,
et al. CXC chemokine KC fails to induce neutrophil inﬁltration and neoan-giogenesis in a mouse model of myocardial infarction. J Mol Cell Cardiol
2013;60:1–7 . 
[44] Liehn EA , Kanzler I , Konschalla S , Kroh A , Simsekyilmaz S , Sonmez TT ,
et al. Compartmentalized protective and detrimental effects of endogenous
macrophage migration-inhibitory factor mediated by CXCR2 in a mouse
model of myocardial ischemia/reperfusion. Arterioscler Thromb Vasc Biol
2013;33:2180–6 . 
[45] Miller EJ , Li J , Leng L , McDonald C , Atsumi T , Bucala R , et al. Macrophage
migration inhibitory factor stimulates AMP-activated protein kinase in the is-
chaemic heart. Nature 2008;451:578–82 . 
[46] Hayashidani S , Tsutsui H , Shiomi T , Ikeuchi M , Matsusaka H , Suematsu N ,
et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left
ventricular remodeling and failure after experimental myocardial infarction.
Circulation 2003;108:2134–40 . 
[47] Martire A , Fernandez B , Buehler A , Strohm C , Schaper J , Zimmermann R ,
et al. Cardiac overexpression of monocyte chemoattractant protein-1 in trans-
genic mice mimics ischemic preconditioning through SAPK/JNK1/2 activation.
Cardiovasc Res 2003;57:523–34 . 
[48] Morimoto H , Hirose M , Takahashi M , Kawaguchi M , Ise H , Kolattukudy PE ,
et al. MCP-1 induces cardioprotection against ischaemia/reperfusion injury:
role of reactive oxygen species. Cardiovasc Res 2008;78:554–62 . 
[49] Montecucco F , Braunersreuther V , Lenglet S , Delattre BM , Pelli G , Buatois V ,
et al. CC chemokine CCL5 plays a central role impacting infarct size and
post-infarction heart failure in mice. Eur Heart J 2012;33:1964–74 . 
[50] Braunersreuther V , Pellieux C . Chemokine CCL5/RANTES inhibition reduces
myocardial reperfusion injury in atherosclerotic mice. J Mol Cell Cardiol
2010;48:789–98 . 
[51] Dobaczewski M , Xia Y , Bujak M , Gonzalez-Quesada C , Frangogiannis NG . CCR5
signaling suppresses inﬂammation and reduces adverse remodeling of the
infarcted heart, mediating recruitment of regulatory T cells. Am J Pathol
2010;176:2177–87 . 
[52] Boyle EM , Kovacich JC . Inhibition of interleukin-8 blocks myocardial ischemi-
a-reperfusion injury. J Thorac Cardiovasc Surg 1998;116:114–21 . 
[53] Zhao X , Zhang W , Xing D , Li P , Fu J , Gong K , et al. Endothelial cells overex-
pressing IL-8 receptor reduce cardiac remodeling and dysfunction following
myocardial infarction. Am J Physiol Heart Circ Physiol 2013;305:H590–8 . 
[54] Abbate A , Kontos MC , Grizzard JD , Biondi-Zoccai GG , Van Tassell BW , Ro-
bati R , et al. Interleukin-1 blockade with anakinra to prevent adverse car-
diac remodeling after acute myocardial infarction (Virginia Commonwealth
University Anakinra Remodeling Trial [VCU-ART] pilot study). Am J Cardiol
2010;105:1371–7 e1 . 
[55] Abbate A , Van Tassell BW , Biondi-Zoccai G , Kontos MC , Grizzard JD , Spill-
man DW , et al. Effects of interleukin-1 blockade with anakinra on ad-
verse cardiac remodeling and heart failure after acute myocardial infarction
[from the Virginia Commonwealth University-Anakinra Remodeling Trial (2)
(VCU-ART2) pilot study. Am J Cardiol 2013;111:1394–400 . 
[56] Abbate A , Kontos MC , Abouzaki NA , Melchior RD , Thomas C , Van Tassell BW ,
et al. Comparative safety of interleukin-1 blockade with anakinra in patients
with ST-segment elevation acute myocardial infarction (from the VCU-ART
and VCU-ART2 pilot studies). Am J Cardiol 2015;115:288–92 . 
[57] Morton AC , Foley C . Investigation of IL-1 inhibition in patients presenting
with non-ST elevation myocardial infarction acute coronary syndromes (the
MRC ILA HEART STUDY). Heart (British Cardiac Society) 2011;97:A13 . 
[58] Morton AC , Rothman AM , Greenwood JP , Gunn J , Chase A , Clarke B , et al. The
effect of interleukin-1 receptor antagonist therapy on markers of inﬂamma-
tion in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study.
Eur Heart J 2015;36:377–84 . 
[59] Ridker PM , Everett BM , Thuren T , MacFadyen JG , Chang WH , Ballantyne C ,
et al. Antiinﬂammatory therapy with canakinumab for atherosclerotic disease.
N Engl J Med 2017;377:1119–31 . 
[60] Abbate A. Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction
(VCU-ART3). Accessed December, 2017: https://clinicaltrials.gov/ct2/show/
NCT01950299 . 
[61] Padﬁeld GJ , Din JN , Koushiappi E , Mills NL , Robinson SD , Cruden Nle M ,
et al. Cardiovascular effects of tumour necrosis factor alpha antagonism in
patients with acute myocardial infarction: a ﬁrst in human study. Heart
2013;99:1330–5 . 
[62] Kleveland O , Kunszt G , Bratlie M , Ueland T , Broch K , Holte E , et al. Effect of
a single dose of the interleukin-6 receptor antagonist tocilizumab on inﬂam-
mation and troponin T release in patients with non-ST-elevation myocardial
infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur
Heart J 2016;37:2406–13 . 
[63] Van Tassell BW , Arena RA , Toldo S , Mezzaroma E , Azam T , Seropian IM ,
et al. Enhanced interleukin-1 activity contributes to exercise intolerance in
patients with systolic heart failure. PLoS One 2012;7:e33438 . 
[64] Haugen E , Tang MS , Isic A , Andersson B , Fu M . TNFalpha antagonist up-
regulates interleukin-6 in rats with hypertensive heart failure. Int J Cardiol
2008;130:64–8 . 
[65] Isic A , Scharin Tang M , Haugen E , Fu M . TNFalpha-antagonist neither improve
cardiac remodelling or cardiac function at early stage of heart failure in dia-
betic rats. Autoimmunity 2008;41:473–7 . 
[66] Li W , Gan R , Sun G . Chronic treatment of enbrel in rats with isoproterenol-in-
duced congestive heart failure limits left ventricular dysfunction and remod-
eling. Chin Med J (Engl) 2002;115:1166–9 . 










































































































 [67] Grimm D , Elsner D , Schunkert H , Pfeifer M , Griese D , Bruckschlegel G ,
et al. Development of heart failure following isoproterenol administration in
the rat: role of the renin-angiotensin system. Cardiovasc Res 1998;37:91–100 .
[68] Moe GW , Marin-Garcia J , Konig A , Goldenthal M , Lu X , Feng Q . In vivo TNF-al-
pha inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress,
and apoptosis in experimental heart failure. Am J Physiol Heart Circ Physiol
2004;287:H1813–20 . 
[69] Van Tassell BW , Arena R , Biondi-Zoccai G , McNair Canada J , Oddi C ,
Abouzaki NA , et al. Effects of interleukin-1 blockade with anakinra on aer-
obic exercise capacity in patients with heart failure and preserved ejection
fraction (from the D-HART pilot study). Am J Cardiol 2014;113:321–7 . 
[70] Van Tassell BW, Canada J, Carbone S, Trankle C, Buckley L, Oddi Erdle C,
et al. Interleukin-1 blockade in recently decompensated systolic heart fail-
ure: results from REDHART (Recently Decompensated Heart Failure Anakinra
Response Trial). Circ Heart Fail 2017;10. doi: 10.1161/CIRCHEARTFAILURE.117.
004373 . 
[71] Van Tassell BW , Abouzaki NA , Oddi Erdle C , Carbone S , Trankle CR , Mel-
chior RD , et al. Interleukin-1 blockade in acute decompensated heart fail-
ure: a randomized, double-blinded, placebo-controlled pilot study. J Cardio-
vasc Pharmacol 2016;67:544–51 . 
[72] Ikonomidis I , Tzortzis S , Lekakis J , Paraskevaidis I , Dasou P , Parissis J , et al. As-
sociation of soluble apoptotic markers with impaired left ventricular defor-
mation in patients with rheumatoid arthritis. Effects of inhibition of inter-
leukin-1 activity by anakinra. Thromb Haemost 2011;106:959–67 . 
[73] Lang RM , Badano LP , Mor-Avi V , Aﬁlalo J , Armstrong A , Ernande L , et al. Rec-
ommendations for cardiac chamber quantiﬁcation by echocardiography in
adults: an update from the American Society of Echocardiography and the
European Association of Cardiovascular Imaging. J Am Soc Echocardiogr
2015;28:1–39 e14 . 
[74] Ikonomidis I , Tzortzis S , Andreadou I , Paraskevaidis I , Katseli C , Katsimbri P ,
et al. Increased beneﬁt of interleukin-1 inhibition on vascular function, my-
ocardial deformation, and twisting in patients with coronary artery disease
and coexisting rheumatoid arthritis. Circ Cardiovasc Imaging 2014;7:619–28 . 
[75] Abbate A. Interleukin-1 blockade with canakinumab to improve exercise
capacity in patients with chronic systolic heart failure and elevated high
sensitivity c-reactive protein (Hs-CRP). Accessed December, 2017: https://
clinicaltrials.gov/ct2/show/NCT0190 060 0 . 
[76] Kotyla PJ , Owczarek A , Rakoczy J , Lewicki M , Kucharz EJ , Emery P . Inﬂix-
imab treatment increases left ventricular ejection fraction in patients with
rheumatoid arthritis: assessment of heart function by echocardiography, en-
dothelin 1, interleukin 6, and NT-pro brain natriuretic peptide. J Rheumatol
2012;39:701–6 . 
[77] Cole J , Busti A , Kazi S . The incidence of new onset congestive heart failure
and heart failure exacerbation in Veteran’s Affairs patients receiving tumor
necrosis factor alpha antagonists. Rheumatol Int 2007;27:369–73 . 
[78] Curtis JR , Kramer JM , Martin C , Saag KG , Patkar N , Shatin D , et al. Heart fail-
ure among younger rheumatoid arthritis and Crohn’s patients exposed to TN-
F-alpha antagonists. Rheumatology (Oxford) 2007;46:1688–93 . 
[79] Listing J , Strangfeld A , Kekow J , Schneider M , Kapelle A , Wassenberg S ,
et al. Does tumor necrosis factor alpha inhibition promote or pre-
vent heart failure in patients with rheumatoid arthritis? Arthritis Rheum
2008;58:667–77 . 
[80] Setoguchi S , Schneeweiss S , Avorn J , Katz JN , Weinblatt ME , Levin R , et al. Tu-
mor necrosis factor-alpha antagonist use and heart failure in elderly patients
with rheumatoid arthritis. Am Heart J 2008;156:336–41 . 
[81] Gasparyan AY , Ayvazyan L , Cocco G , Kitas GD . Adverse cardiovascular effects
of antirheumatic drugs: implications for clinical practice and research. Curr
Pharm Des 2012;18:1543–55 . 
[82] Greenberg JD , Kremer JM . Tumour necrosis factor antagonist use and associ-
ated risk reduction of cardiovascular events among patients with rheumatoid
arthritis. Ann Rheum Dis. 2011;70:576–82 . 
[83] Wolfe F , Michaud K . Heart failure in rheumatoid arthritis: rates, predic-
tors, and the effect of anti-tumor necrosis factor therapy. Am J Med
2004;116:305–11 . 
[84] Jacobsson LT , Turesson C , Gulfe A , Kapetanovic MC , Petersson IF , Saxne T ,
et al. Treatment with tumor necrosis factor blockers is associated with a
lower incidence of ﬁrst cardiovascular events in patients with rheumatoid
arthritis. J Rheumatol 2005;32:1213–18 . 
[85] Bozkurt B , Torre-Amione G , Warren MS , Whitmore J , Soran OZ , Feld-
man AM , et al. Results of targeted anti-tumor necrosis factor therapy with
etanercept (ENBREL) in patients with advanced heart failure. Circulation
2001;103:1044–7 . 
[86] Deswal A , Bozkurt B , Seta Y , Parilti-Eiswirth S , Hayes FA , Blosch C , et al. Safety
and eﬃcacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etaner-
cept) in patients with advanced heart failure. Circulation 1999;99:3224–6 . [87] Fichtlscherer S , Rossig L , Breuer S , Vasa M , Dimmeler S , Zeiher AM . Tu-
mor necrosis factor antagonism with etanercept improves systemic en-
dothelial vasoreactivity in patients with advanced heart failure. Circulation
2001;104:3023–5 . 
[88] Chung ES , Packer M , Lo KH , Fasanmade AA , Willerson JT . Anti-TNF ther-
apy against congestive heart failure investigators. Randomized, double-blind,
placebo-controlled, pilot trial of inﬂiximab, a chimeric monoclonal antibody
to tumor necrosis factor-alpha, in patients with moderate-to-severe heart fail-
ure: results of the anti-TNF Therapy Against Congestive Heart Failure (AT-
TACH) trial. Circulation 2003;107:3133–40 . 
[89] Mann DL , McMurray JJ , Packer M , Swedberg K , Borer JS , Colucci WS , et al. Tar-
geted anticytokine therapy in patients with chronic heart failure: results of
the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation
2004;109:1594–602 . 
[90] White CA , Nicola NA . SOCS3: An essential physiological inhibitor of signaling
by interleukin-6 and G-CSF family cytokines. JAKSTAT 2013;2:e25045 . 
[91] Gibson MS , Kaiser P , Fife M . The chicken IL-1 family: evolution in the context
of the studied vertebrate lineage. Immunogenetics 2014;66:427–38 . 
[92] Fontes JA , Rose NR , Cihakova D . The varying faces of IL-6: From cardiac pro-
tection to cardiac failure. Cytokine 2015;74:62–8 . 
[93] Kishore R , Tkebuchava T , Sasi SP , Silver M , Gilbert HY , Yoon YS , et al. Tu-
mor necrosis factor-alpha signaling via TNFR1/p55 is deleterious whereas
TNFR2/p75 signaling is protective in adult infarct myocardium. Adv Exp Med
Biol 2011;691:433–48 . 
[94] Monden Y , Kubota T , Inoue T , Tsutsumi T , Kawano S , Ide T , et al. Tumor
necrosis factor-alpha is toxic via receptor 1 and protective via receptor 2
in a murine model of myocardial infarction. Am J Physiol Heart Circ Physiol
2007;293:H743–53 . 
[95] Kurdi A , De Meyer GR , Martinet W . Potential therapeutic effects of mTOR in-
hibition in atherosclerosis. Br J Clin Pharmacol 2016;82:1267–79 . 
[96] Martinet W , De Loof H , De Meyer GR . mTOR inhibition: a promising strategy
for stabilization of atherosclerotic plaques. Atherosclerosis 2014;233:601–7 . 
[97] van Zuylen VL , den Haan MC , Roelofs H , Fibbe WE , Schalij MJ , Atsma DE . My-
ocardial infarction models in NOD/Scid mice for cell therapy research: perma-
nent ischemia vs ischemia-reperfusion. Springerplus 2015;4 336-015-1128-y. 
eCollection 2015 . 
[98] Moro C , Jouan MG , Rakotovao A , Toufektsian MC , Ormezzano O , Nagy N ,
et al. Delayed expression of cytokines after reperfused myocardial infarc-
tion: possible trigger for cardiac dysfunction and ventricular remodeling. Am
J Physiol Heart Circ Physiol 2007;293:H3014–19 . 
[99] Chimenti S , Carlo E , Masson S , Bai A , Latini R . Myocardial infarction: animal
models. Methods Mol Med 2004;98:217–26 . 
100] Qazi BS , Tang K , Qazi A . Recent advances in underlying pathologies provide
insight into interleukin-8 expression-mediated inﬂammation and angiogene-
sis. Int J Inﬂam 2011;2011:908468 . 
[101] Lara-Pezzi E , Menasche P , Trouvin JH , Badimon L , Ioannidis JP , Wu JC ,
et al. Guidelines for translational research in heart failure. J Cardiovasc Transl
Res 2015;8:3–22 . 
[102] Christia P , Bujak M , Gonzalez-Quesada C , Chen W , Dobaczewski M , Reddy A ,
et al. Systematic characterization of myocardial inﬂammation, repair, and re-
modeling in a mouse model of reperfused myocardial infarction. J Histochem
Cytochem 2013;61:555–70 . 
[103] Steg PG , James SK , Atar D , Badano LP , Blomstrom-Lundqvist C , et al. , Task
Force on the management of ST-segment elevation acute myocardial infarc-
tion of the European Society of Cardiology (ESC) ESC guidelines for the man-
agement of acute myocardial infarction in patients presenting with ST-seg-
ment elevation. Eur Heart J 2012;33:2569–619 . 
104] Lenzen MJ , Scholte op Reimer WJ . Differences between patients with a pre-
served and a depressed left ventricular function: a report from the EuroHeart
Failure Survey. Eur Heart J 2004;25:1214–20 . 
[105] Shah AM , Claggett B , Sweitzer NK , Shah SJ , Anand IS , O’Meara E , et al. Cardiac
structure and function and prognosis in heart failure with preserved ejection
fraction: ﬁndings from the echocardiographic study of the Treatment of Pre-
served Cardiac Function Heart Failure with an Aldosterone Antagonist (TOP-
CAT) Trial. Circ Heart Fail 2014;7:740–51 . 
106] Dixon WG , Watson KD , Lunt M , Hyrich KL , Silman AJ , et al. , British Soci-
ety for Rheumatology Biologics Register Control Centre Consortium Reduc-
tion in the incidence of myocardial infarction in patients with rheumatoid
arthritis who respond to anti-tumor necrosis factor alpha therapy: results
from the British Society for Rheumatology Biologics Register. Arthritis Rheum
2007;56:2905–12 . 
